New England Journal of Medicine· 2014Q1

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

John C. Byrd, Jennifer R. Brown, Susan O’Brien, Jacqueline C. Barrientos et al.

1,629citations
Q1SCImago
2014year

Short summary

Ibrutinib significantly improved progression-free survival (median not reached vs. 8.1 months), overall survival (90% vs. 81% at 12 months), and response rate (42.6% vs. 4.1%) compared to ofatumumab in previously treated chronic lymphoid leukemia (CLL) patients.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Genetics

GeneticsMedicine